Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for clues to why clozapine works for some with schizophrenia

NCT ID NCT05316883

Knowledge-focused Sponsor: Jimmi Nielsen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at 200 people with treatment-resistant schizophrenia who are starting clozapine. Researchers will measure immune markers in blood and spinal fluid, brain scans, and other tests before and after 12 weeks of treatment. The goal is to find biological signs that predict who will respond well to clozapine, which could help tailor treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Clozapine
What this could lead to
If successful, this could help doctors identify which patients are most likely to respond to clozapine, leading to more personalized treatment for schizophrenia.
What could go wrong
This is an observational study focused on biomarkers, not a treatment trial. It may not directly improve outcomes, and results may not apply to all patients with schizophrenia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2021

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * According to ICD-10 fulfill diagnostic criteria for schizophrenia (F20.x), chronical paranoid psychoses (F22), Schizoaffective psychoses (F25) or other non-organic psychoses (F28/F29); * Age 18-65 years; * Legally competent; * Stabil antipsychotic treatment during last month * Being treatment refractory according to TRIPP-guidelines (Howes et al. 2017) defined as having tried at least two antipsychotic drugs in sufficient dosage (≥600 mg chlorpromazine equivalent) for a sufficient time (≥ 6 weeks) without sufficient symptom improvement (still a moderate level of positive symptoms). * Recreational use of substances is allowed as long as it does not interfere with compliance * Fertile females must use safe contraception (spiral or any hormonal contraception). Exclusion Criteria: * Involuntarily psychiatric admittance during the study * Substance abuse that interfere with compliance * Pregnancy (will be verified by urine-HCG-test in fertile females) * Toxic or idiosyncratic agranulocytosis in the past * Reduced bone marrow function according to blood samples * According to information from patient and available files, noUncontrolled * Current uncontrolled epilepsy * Current circulatory collapse and / or CNS depression for any cause * Current severe kidney, heart or liver disease * Current paralytic ileus

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic paranoid psychosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

paranoid schizophrenia psychotic disorder Psychotic Disorders schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psychosis Schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mental Health Services Glostrup, Unit for Complicated Schizophrenia

    RECRUITING

    Glostrup Municipality, Denmark, 2600, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.